Unlock insights into multiple cancers with just 10 ng total nucleic acid input
Experience our innovative, single-day sample to sequencing workflow for simultaneous enrichment and profiling of 605 relevant DNA variant and RNA fusion biomarkers found across multiple cancers, as well as assessment of tumor mutational burden (TMB) and microsatellite instability (MSI), from a single sample input of 10 ng.
Hover-over to reveal the details
Targets genes and RNA fusions implicated in the pathogenesis of solid and heme malignancies
Assess key immunotherapy biomarkers:
Enables detection of
Unique molecular indices (UMIs) and Unique dual indices (UDIs) included
Other QIAseq Multimodal Panels
Nucleic acid isolation
In this webinar, we explore a new workflow for simultaneous NGS profiling of both DNA variants and RNA fusions, as well as gene expression in just one day, using as little as 10 ng sample. We’ll discuss:
In this webinar, we will take you through an introduction and live demo of the QIAGEN CLC Genomics Workbench workflow for multimodal analysis. Discover this intuitive yet powerful solution tailored for analysis of NGS data generated with QIAseq Multimodal Panels.
In this webinar, Vincent Funari of NeoGenomics will discuss how his team has evolved its profiling approaches for both heme and solid tumors from targeted panels to more comprehensive genomic profiling.
Dr. Funari will highlight tools that enable a more streamlined path for adopting CGP, enabling operational efficiencies such as reduced overall cost while delivering high-quality data. He will also share additional insights his team gained into alterations that were previously missed due to limitations of current technologies.
In this webinar, we’ll discuss customized solutions for optimized workflows to address specific applications, powered by our Enterprise Genomics Services (EGS). This is a concierge-style approach to project design and management, built upon years of experience in development and rapid integration of custom solutions into the laboratory. Our tailored solutions leverage QIAGEN’s extensive Knowledge Base of approximately 15 million biological findings, automated solutions for operational efficiency and supporting bioinformatics pipelines. As your technical development partner, QIAGEN will work with you directly to build the optimal solution to power your research.
In this webinar, Dr. Herold will discuss how her team has streamlined the profiling of cancer-associated alterations by using a single workflow for the construction of libraries from total nucleic acids for sequencing on Illumina platforms to achieve high operational efficiency. Alterations include low-frequency single nucleotide variants (SNVs), InDels, NTRK fusions and MET exon 14 skipping.
Presenter: Dr. Sylvia Herold, Institut für Pathologie, Universitätsklinikum Dresden, Germany
Thank you for your feedback.
* Mandatory fields